Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21107114 | 0.85 | KDM4C (0.34) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL29868781 | 0.85 | KDM4C (0.34) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL21107344 | 0.83 | SLCO1B1 (0.35) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL29869865 | 0.83 | SLCO1B1 (0.35) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL21107329 | 0.82 | SLCO1B1 (0.39) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL29869171 | 0.79 | KDM4C (0.35) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL22467487 | 0.79 | KDM4C (0.35) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL29634339 | 0.78 | SLCO1B1 (0.37) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL22467484 | 0.78 | SLCO1B1 (0.37) | LPAR1KDM4CNPC1RAB9ASLCO1B1 | |
| SCHEMBL21807809 | 0.78 | LPAR1 (0.37) | LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| EP-3852746-A1 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020060915-A1 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | LPAR1, LPAR5, LPAR2 | LPAR1 1/4885KDM4C 4235/4885NPC1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.